knowledge -WSS

knowledge

author：hotspot 2025-10-02 23:59:58 - browse：8886

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Patients, digital health players weigh in on FTC's data privacy plan

WSS

Illumina slashes 2023 revenue projections yet again

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

After Optum profits sink, UnitedHealth makes changes

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

Illumina slashes 2023 revenue projections yet again

Wikipedia

knowledge

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

What does generative AI mean for health care? We asked experts

Novo Nordisk touts Wegovy study, but still struggling with supply

Wildfire smoke exposes gaps in outdoor worker protections

Treatments for cramps don't cut it. Why aren't there better options?

Duchenne breakthrough therapy leaves behind pioneering families

Adele warns fans about throwing things at performers onstage

What does generative AI mean for health care? We asked experts

5 shark bites reported on Long Island as officials deploy surveillance drones

entertainment

Princess Kate attends Wimbledon with Roger Federer: See the photos

1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates

Treatments for cramps don't cut it. Why aren't there better options?

The leaders of Italy and Poland say European Union should focus on stopping migration

Treatments for cramps don't cut it. Why aren't there better options?

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

focus

hotspot

entertainment

focus